Yuhan Corp

Yuhan Corp maintains a strong liquidity position, with a current ratio of 2.06 and cash and equivalents amounting to KRW 348.5 billion, which is well above the industry median for liquidity coverage. The company's debt-to-equity ratio of 0.15 indicates a conservative capital structure, with long-term debt at KRW 343.2 billion and total equity at KRW 2.3 trillion. This low leverage supports financial flexibility and reduces refinancing risk. Profitability metrics show a return on equity (ROE) of 8.41% and a return on assets (ROA) of 6.03%, both of which are in line with the industry median for pharmaceutical firms. The company's gross margin is 33.4% (KRW 729.9 billion gross profit on KRW 2.19 trillion revenue), and operating margin is 8.42% (KRW 184.2 billion operating income), which are consistent with the sector's average profitability. Geographically, Yuhan Corp is heavily concentrated in the South Korean market, with no disclosed international revenue segments. This concentration exposes the company to domestic regulatory and pricing pressures, which are key geopolitical drivers for the pharmaceutical industry. Looking ahead, Yuhan Corp is projected to grow revenue by 4.5% in the current fiscal year and 3.2% in the next, based on analyst estimates and historical performance. The company's free cash flow of KRW 68.5 billion supports reinvestment and shareholder returns, though capital expenditures are negative, indicating asset sales or reduced investment in physical infrastructure. Risk factors include potential regulatory changes in South Korea, which could impact pricing and reimbursement policies. However, the company's low dilution risk and strong liquidity position mitigate near-term financial stress. No immediate dilution events are flagged, and the company's shares outstanding remain unchanged between basic and diluted shares. Recent filings and transcripts indicate no material changes in the company's strategic direction or financial outlook. Analysts remain cautiously optimistic, with a mean price target of KRW 129,538.46 and a median of KRW 140,000, suggesting a potential upside from the current market price of KRW 86,000.